[Skip to Content]
[Skip to Content Landing]
Views 400
Citations 0
Research Letter
November 27, 2019

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

Author Affiliations
  • 1Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
  • 2Department of Infection Prevention and Control, University Health Network, Toronto, Ontario, Canada
  • 3Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 4Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
JAMA Oncol. Published online November 27, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.5098

Daratumumab is a human immunoglobulin G1κ monoclonal antibody directed against cluster of differentiation (CD) 38 that received US Food and Drug Administration approval in 2017 as multiple myeloma therapy. While CD38 is highly expressed by myeloma cells, it is also expressed by activated macrophages and appears to play an important role in Listeria defense, inhibiting the infection of the macrophage cytoplasm by phagocytosed bacilli and preventing macrophage-based dissemination.1 In mice, CD38 inactivation causes a marked susceptibility to Listeria monocytogenes. As CD38 is also induced on human macrophages, identical mechanisms may underlie human Listeria protection.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words